US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

Amgen’s Uplizna (inebilizumab-cdon) has shown sustained efficacy in a group of gMG patients after 52 weeks in a Phase III ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- A newly identified part of a brain circuit mixes sensory information, memories, and emotions to tell whether things are familiar or new, and important or ...

BALTIMORE, Feb. 12, 2025 /PRNewswire/ -- Today, Previse, a gastrointestinal health company, announced a newly published study in the American Journal of Gastroenterology, which provides additional ...

However, analysts note that its efficacy in AChR+ patients, who represent the majority of gMG cases, may not surpass current standards of care. Amgen's oncology portfolio continues to evolve ...